Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in China
Pengfei Zou,Yunjiao Bi,Zhaowei Tong,Tao Wu,Qiang Li,Kai Wang,Yuchen Fan,Dan Zhao,Xin Wang,Hui Shao,Haijun Huang,Suping Ma,Yunsong Qian,Guoqiang Zhang,Xiao Liu,Qiaofei Jin,Qingjing Ru,Zhiping Qian,Wei Sun,Qiang Chen,Liying You,Fang Wang,Xiaoting Zhang,ZhenXiong Qiu,Qing Lin,Jiaojian Lv,Yongping Zhang,Jiawei Geng,Richeng Mao,Jinfeng Liu,Yubao Zheng,Feng Ding,Hui Wang,Hainv Gao
DOI: https://doi.org/10.1186/s13063-024-08578-9
IF: 2.728
2024-11-29
Trials
Abstract:Hepatic encephalopathy (HE) represents a critical complications of end-stage liver disease, serving as an independent predictor of mortality among patients with cirrhosis. Despite effective treatment with rifaximin, some patients with HE still progress to recurrent episodes, posing a significant therapeutic challenge. Recurrent HE is defined as experiencing two or more episodes within a 6-month period. Previous research has suggested that FMT may emerge as a promising treatment for recurrent HE. However, there remains a critical need to explore the optimal dosage. This trial aims to abscess the efficacy and safety of two FMT dosages: 800 ml or 400 ml total bacterial count, including mortality and quality of life.
medicine, research & experimental